Colesevelam Hcl

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nonalcoholic Steatohepatitis

Conditions

Nonalcoholic Steatohepatitis

Trial Timeline

Feb 1, 2010 → Feb 1, 2012

About Colesevelam Hcl

Colesevelam Hcl is a phase 2 stage product being developed by Daiichi Sankyo for Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01066364. Target conditions include Nonalcoholic Steatohepatitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT01066364Phase 2Completed
NCT00476710Pre-clinicalCompleted

Competing Products

20 competing products in Nonalcoholic Steatohepatitis

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
LanifibranorInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
Tirzepatide + PlaceboEli LillyPhase 2
52
AZD2693AstraZenecaPhase 2
52
Roflumilast + Pioglitazone + Placebo + PlaceboAstraZenecaPhase 2
52
MK-3655 + PlaceboMerckPhase 2
52
Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mLMerckPhase 2
52
SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mgGilead SciencesPhase 3
76
Seladelpar + PlacebosGilead SciencesPhase 2
51
CilofexorGilead SciencesPhase 1
32
Firsocostat + FenofibrateGilead SciencesPhase 1
32
GS-9674 + Placebo to match GS-9674Gilead SciencesPhase 2
51
SEL + FIR + CILO + Placebo to match FIR + Placebo to match CILO + Placebo to match SELGilead SciencesPhase 2
51
GS-9450 + GS-9450 PlaceboGilead SciencesPhase 2
51
Semaglutide + Firsocostat + CilofexorGilead SciencesPhase 2
51